LAB vs. QTRX, EYPT, CTKB, PACB, ADPT, NAUT, AKYA, TMCI, HLVX, and BCYC
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), Cytek Biosciences (CTKB), Pacific Biosciences of California (PACB), Adaptive Biotechnologies (ADPT), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Treace Medical Concepts (TMCI), HilleVax (HLVX), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
Standard BioTools (NASDAQ:LAB) and Quanterix (NASDAQ:QTRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations, community ranking and media sentiment.
Standard BioTools has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Quanterix has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.
In the previous week, Quanterix had 2 more articles in the media than Standard BioTools. MarketBeat recorded 8 mentions for Quanterix and 6 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.52 beat Quanterix's score of 1.01 indicating that Standard BioTools is being referred to more favorably in the media.
Quanterix received 264 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
Quanterix has higher revenue and earnings than Standard BioTools. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Standard BioTools presently has a consensus target price of $3.58, indicating a potential upside of 39.43%. Quanterix has a consensus target price of $30.60, indicating a potential upside of 76.47%. Given Quanterix's stronger consensus rating and higher possible upside, analysts plainly believe Quanterix is more favorable than Standard BioTools.
53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 86.5% of Quanterix shares are held by institutional investors. 53.1% of Standard BioTools shares are held by company insiders. Comparatively, 6.9% of Quanterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Quanterix has a net margin of -28.82% compared to Standard BioTools' net margin of -70.98%. Quanterix's return on equity of -10.39% beat Standard BioTools' return on equity.
Summary
Quanterix beats Standard BioTools on 13 of the 19 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
